title: Novel therapies for Helicobacter pylori infection.
abstract: BACKGROUND
  Increasing antibiotic resistance has begun to impair our ability to cure Helicobacter pylori infection.
  
  
  OBJECTIVE
  To evaluate orally administered novel therapies for the treatment of H. pylori infection.
  
  
  METHODS
  Healthy H. pylori infected volunteers received: (a) hyperimmune bovine colostral immune globulins, (b) an oligosaccharide containing an H. pylori adhesion target, Neu5Aca2-3Galb1-4Glc-(3'-sialyllactose), or (c) recombinant human lactoferrin. Outcome was assessed by urea breath test or histological assessment of the number of H. pylori present.
  
  
  RESULTS
  None of the novel therapies appeared effective and no adverse events occurred.
  
  
  CONCLUSIONS
  Although in vitro data appeared promising, in vivo results were disappointing. Higher doses, longer duration of therapy, adjunctive acid suppression, or a combination could possibly yield better results.
authors.affiliation: Department of Medicine, Baylor College of Medicine, Texas Children's Hospital, Veterans Affairs Medical Center, Houston 77030, USA.
authors.forename: A R
authors.initials: AR
authors.lastname: Opekun
authors.forename: H M
authors.initials: HM
authors.lastname: El-Zaimaity
authors.forename: M S
authors.initials: MS
authors.lastname: Osato
authors.forename: M A
authors.initials: MA
authors.lastname: Gilger
authors.forename: H M
authors.initials: HM
authors.lastname: Malaty
authors.forename: M
authors.initials: M
authors.lastname: Terry
authors.forename: D R
authors.initials: DR
authors.lastname: Headon
authors.forename: D Y
authors.initials: DY
authors.lastname: Graham
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000818:Animals; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001944:Breath Tests / Q000379:methods; D002417:Cattle; D003126:Colostrum / Q000276:immunology; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007781:Lactoferrin / Q000627:therapeutic use*; D007785:Lactose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D012794:Sialic Acids / Q000627:therapeutic use*; D016896:Treatment Outcome; D014508:Urea
chemical_list: D000276:Adjuvants, Immunologic; D000897:Anti-Ulcer Agents; D007074:Immunoglobulin G; D011994:Recombinant Proteins; D012794:Sialic Acids; C000020:N-acetylneuraminoyllactose; D014508:Urea; D007781:Lactoferrin; D007785:Lactose